Financings
Affinium Pharmaceuticals Inc. raised $15 million in a Series B financing.
Ardelyx Inc. closed a $30 million Series B round for its Phase II irritable bowel drug.
OrbiMed Advisors LLC jumped into the royalty monetization game, raising a $600 million fund.
Deals
Adimab LLC inked antibody discovery deals with Biogen Idec Inc. and Novo Nordisk A/S.
Afexa Life Sciences Inc. agreed to a $77 million acquisition by Valeant Pharmaceuticals International Inc.
Synageva BioPharma Corp. signed an orphan disease research deal with Mitsubishi Tanabe Pharma Corp.
Zymeworks Inc. signed a $187 million deal with Merck & Co. Inc. for bispecific antibody discovery.
. . . And More
Aeterna Zentaris Inc.'s AEZS-130 met its endpoint in Phase III as a diagnostic for growth hormone deficiency.
Amsterdam Molecular Therapeutics NV cut costs as it gears up for an extension trial with gene therapy Glybera.
Clavis Pharma ASA expanded its pivotal Phase III trial of elacytarabine in acute myeloid leukemia.
Curacyte AG terminated its Phase III trial of PHP/Hemoximer for distributive shock due to futility.
Cytos Biotechnology Ltd. is reducing its workforce and board to conserve capital.
NuPathe Inc.'s Zelrix (sumatriptan patch) for migraine got an FDA complete response letter.
Oxigene Inc. restructured and delayed a pivotal Zybrestat (fosbretabulin tromethamine) trial.
Pfizer Inc. gained FDA approval of lung cancer drug Xalkori (crizotinib), paired with a diagnostic from Abbott.